Trial · NCT04274426
Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer
NCT04274426, Phase 2, Active not recruiting, AGO Research GmbH
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer. Trials, record NCT04274426. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04274426
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer
- NCT number
- NCT04274426
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 136 participants, estimated
- Lead sponsor
- AGO Research GmbH
- Conditions
- Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
- Interventions
- Carboplatin, Pegylated liposomal doxorubicin (PLD), Gemcitabine, Paclitaxel, Mirvetuximab Soravtansine
- First posted
- 2020-02-18
- Last updated
- 2026-05-13
- Other registries' IDs
- eudract:2018-004207-39
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression free survival (PFS) defined as the time from randomization to progressive disease (PD) or death, whichever occurs earlier. PD is based on investigator assessment using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). | Up to 2.5 years. From date of randomization until date of progressive disease (PD) or death, whichever occurs earlier. | PD is based on investigator assessment using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). |
| Secondary | OS | Up to 2.5 years. From date of randomization until date of death from any cause. | Overall survival |
| Secondary | ORR | Up to 2.5 years. From date of randomization to date of death death from any cause. | Objective response rate |
| Secondary | Efficacy regarding PFS | Up to 2.5 years. From date of randomization to date of death from any cause. | Efficacy regarding Progression Free Survival depending on histologic subtype |
| Secondary | Efficacy regarding OS | Up to 2.5 years. From date of randomization to date of death from any cause. | Efficacy regarding Overall Survival depending on histologic subtype |
| Secondary | Efficacy regarding ORR | Up to 2.5 years. From date of randomization to date of death from any cause. | Efficacy regarding Objective Response Rate depending on histologic subtype |
| Secondary | Serological progressive disease | Up to 2.5 years. From date of randomization to date of death death from any cause. | Time to serological progressive disease according to GCIG criteria |
| Secondary | Time to first subsequent treatment (TFST) | Up to 2.5 years. From date of randomization to date of death from any cause. | Time to first subsequent treatment (TFST) |
| Secondary | Time to second subsequent treatment (TSST) | Up to 2.5 years. From date of randomization until date of death from any cause. | Time to second subsequent treatment (TSST) |
| Secondary | Patient-reported outcomes | Up to 2.5 years. From date of randomization until date of death from any cause. | Quality of Life (EORTC C-30) |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04274426
GET https://conductscience.org/api/trials/v1/NCT04274426/registered